On this page, Beliefnet is publishing articles provided by Forest Pharmaceuticals, the makers of Lexapro. Forest Pharmaceuticals is solely responsible for this content.

Depression with Anxiety Often Coexist

People suffering from depression often experience anxiety as well. In fact, as many as 90% of people who've been diagnosed with depression also have symptoms of anxiety.1 Similarly, it is common for people diagnosed with generalized anxiety disorder (GAD) to also receive a diagnosis of depression. If anxiety symptoms appear along with depression, it doesn't necessarily mean you have GAD. Be sure to tell your doctor about all of your symptoms so you will get the right diagnosis.

Depression and Anxiety Require Medical Attention

Whether you suffer from depression, anxiety, or both, it is important to seek the care of a healthcare professional. Depression and anxiety are serious illnesses that require medical attention. If you suffer from either of these disorders, you are not alone. According to the National Institute of Mental Health, almost 15 million U.S. adults have depression in a given year2 and about 6.8 million suffer from GAD.3 Men and women of all ages are affected. The good news is that depression and GAD are both treatable.

Lexapro® Offers Convenient Treatment for Both Disorders

If you suffer from both depression and/or GAD, you should ask your doctor about LEXAPRO. For most people, one 10 mg tablet a day of Lexapro controls the symptoms of either of these disorders. With a simple dosing schedule of only one tablet daily, LEXAPRO makes it easy for you to take your medicine on schedule and keep your symptoms under control.

References: 1. Kaplan HI, Sadock BJ. Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins;1998:553. 2. National Institute of Mental Health. Gene Variants Protect Against Adult Depression Triggered by Childhood Stress. Available at: Accessed June 10, 2008. 3. Kessler RC, Chiu WT, Demler O,Walters EE. Prevalence, severity, and comorbidity of twelve month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry. 2005; 62(6):617–627.


Join the Discussion
comments powered by Disqus